• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.

作者信息

Patoulias Dimitrios, Michailidis Theodoros, Papadopoulos Christodoulos, Karagiannis Asterios, Doumas Michael

机构信息

Second Propedeutic Department of Internal Medicine.

Second Department of Internal Medicine.

出版信息

Am J Cardiol. 2022 Mar 1;166:144-145. doi: 10.1016/j.amjcard.2021.12.001. Epub 2021 Dec 30.

DOI:10.1016/j.amjcard.2021.12.001
PMID:34974899
Abstract
摘要

相似文献

1
Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.评估双重葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1受体激动剂对2型糖尿病患者血压水平影响的随机对照试验的Meta分析
Am J Cardiol. 2022 Mar 1;166:144-145. doi: 10.1016/j.amjcard.2021.12.001. Epub 2021 Dec 30.
2
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.替尔泊肽：一种葡萄糖依赖性胰岛素促泌多肽（GIP）和胰高血糖素样肽-1（GLP-1）双重激动剂，正在开发用于治疗 2 型糖尿病。
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
3
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
4
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.关于“双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂替尔泊肽对2型糖尿病患者心率的影响：一项系统评价及成对和网状荟萃分析”中替尔泊肽与胰高血糖素样肽-1受体激动剂及心率的评论
Diabetes Obes Metab. 2024 Mar;26(3):1138-1141. doi: 10.1111/dom.15381. Epub 2023 Nov 28.
5
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.高剂量胰高血糖素样肽-1、胰高血糖素样肽-1/葡萄糖依赖性胰岛素释放肽和胰高血糖素样肽-1/胰高血糖素受体激动剂在 2 型糖尿病中的疗效和安全性。
Diabetes Obes Metab. 2022 May;24(5):788-805. doi: 10.1111/dom.14640. Epub 2022 Jan 21.
6
Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?西他列汀对2型糖尿病患者十二指肠内输注葡萄糖后血压和心率的影响：葡萄糖依赖性促胰岛素多肽的潜在作用？
Diabet Med. 2015 May;32(5):595-600. doi: 10.1111/dme.12622. Epub 2014 Nov 11.
7
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
8
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.基于随机对照试验的系统评价和荟萃分析：相较于单独使用钠-葡萄糖共转运蛋白 2 抑制剂，胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖共转运蛋白 2 抑制剂在血糖疗效和安全性方面的表现。
Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13.
9
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.LY3298176，一种新型双重 GIP 和 GLP-1 受体激动剂，用于治疗 2 型糖尿病：从发现到临床概念验证。
Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3.
10
[Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].[2型糖尿病中肠促胰岛素水平及活性的药物调节潜力]
Biomed Khim. 2015 Jul-Aug;61(4):488-96. doi: 10.18097/PBMC20156104488.

引用本文的文献

1
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.与胰高血糖素样肽-1（GLP-1）受体激动剂相比，双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂的降压疗效
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD016144. doi: 10.1002/14651858.CD016144.
2
Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?替尔泊肽：迄今为止的证据是否表明其具有治疗早期2型糖尿病的潜力？
Ther Clin Risk Manag. 2022 Sep 28;18:955-964. doi: 10.2147/TCRM.S328056. eCollection 2022.